The Darkest Hour Is After DAYBREAK For Lundbeck’s New Antipsychotic
Executive Summary
The first Phase III study for Lundbeck’s novel antipsychotic flops leaving the Danish company shares down by 25% as investors wonder what’s left in the pipeline.
You may also be interested in...
Lundbeck Looks To Pipeline As Generic Competition Hits
Lundbeck highlighted R&D and the strong growth of four strategic products in the first half, as revenues were hit by generic competitors to top-selling products.
Pressure Builds On Lundbeck After Rexulti Fails In Bipolar I Manic Episodes
Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.
Lundbeck Launches Rexulti In Europe, Phase II LU AF11167 Trial In Schizophrenia
Danish CNS specialist begins Rexulti roll-out in Europe and proof-of-concept study of its early pipeline candidate Lu AF11167.